Working...
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT03898180
Brief Title: Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

First Submitted : March 29, 2019
First Submitted that Met QC Criteria : March 29, 2019
First Posted : April 1, 2019

Last Update Submitted that Met QC Criteria : July 17, 2019
Last Update Posted : July 18, 2019